SLC5A2 and heart failure: Hence, this systematic review was undertaken to investigate and compare the long-term benefits of SGLT2 inhibitors versus MRAs in treating heart failure, regardless of ejection fraction and aetiology, by comparing the rates of worsening heart failure events and cardiovascular deaths.